Aurora Kinase B Market Report 2026

The aurora kinase b market size has grown rapidly in recent years. It will grow from $1.27 billion in 2025 to $1.43 billion in 2026 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to advancements in molecular oncology research, identification of aurora kinase b as a cancer target, expansion of clinical trial infrastructure, increasing investment in targeted cancer therapies, progress in kinase inhibitor development.

The aurora kinase b market size is expected to see rapid growth in the next few years. It will grow to $2.22 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to increasing demand for precision cancer therapeutics, expansion of personalized medicine approaches, rising oncology clinical trial activity, growing investments in novel kinase inhibitors, improved regulatory support for targeted oncology drugs. Major trends in the forecast period include increasing development of selective aurora kinase b inhibitors, growing emphasis on combination oncology therapies, expansion of precision oncology drug pipelines, rising focus on mitotic targeted therapies, improved biomarker-based patient stratification.

The rising incidence of cancer is expected to accelerate the growth of the aurora kinase B market. Cancer is a group of diseases characterized by uncontrolled cell growth, which can spread to surrounding tissues and metastasize to other parts of the body. Factors such as an aging population, lifestyle changes, environmental exposures, and improved detection are contributing to the increase in cancer cases. Aurora kinase B plays a crucial role in mitosis, and its overexpression is linked to chromosomal instability and cancer progression, making it a key target for cancer therapies. For example, in February 2024, the World Health Organization (WHO) estimated that 20 million new cancer cases were reported globally in 2022, along with 9.7 million deaths. By 2050, the number of new cancer cases is expected to surpass 35 million, reflecting a 77% increase from 2022. Therefore, the increasing cancer incidence is driving the growth of the aurora kinase B market.

Leading companies in the aurora kinase B market are developing innovative products, such as aurora kinase inhibitors, to specifically target and disrupt cell division processes. These inhibitors aim to block the activity of aurora kinases, which are critical for cell division, thus potentially reducing tumor growth. For example, in June 2023, Ellipses Pharma, a UK-based biotechnology company, received FDA approval for EP0042, a dual FLT-3 and aurora kinase inhibitor. EP0042 is being developed as a treatment for acute myeloid leukemia (AML), targeting both FLT3 and aurora kinase. This approach aims to treat AML patients who have developed resistance to FLT3 inhibitors, with research showing that dual inhibition can overcome resistance both in vitro and in vivo.

In June 2024, Gedeon Richter Plc., a Hungary-based pharmaceutical company, acquired BCI Pharma for $13.3 million. This acquisition strengthens Richter's ability to develop targeted treatments in oncology and other therapeutic areas, as BCI Pharma is a Belgium-based manufacturer of aurora kinase B inhibitors.

Major companies operating in the aurora kinase b market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Amgen Inc., Astellas Pharma Inc., Promega Corporation, Rigel Pharmaceuticals Inc., Tocris Bioscience, BPS Bioscience Inc., Advenchen Laboratories LLC, Shenzhen Chipscreen Biosciences Co. Ltd., Cyclacel Pharmaceuticals Inc., Sareum Holdings plc.

North America was the largest region in the aurora kinase B market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the aurora kinase b market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the aurora kinase b market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are influencing the aurora kinase b market by increasing costs of imported active pharmaceutical ingredients, laboratory reagents, bioprocessing equipment, and analytical instruments used in drug discovery and clinical development. Research institutes and pharmaceutical developers in North America and Europe are most affected due to reliance on specialized imported inputs, while Asia-Pacific faces higher costs for exporting investigational compounds. These tariffs are extending development timelines and increasing R&D expenditures. At the same time, they are encouraging localized API manufacturing, regional research collaborations, and domestic capacity building in advanced oncology drug development.

The aurora kinase b market research report is one of a series of new reports that provides aurora kinase b market statistics, including aurora kinase b industry global market size, regional shares, competitors with a aurora kinase b market share, detailed aurora kinase b market segments, market trends and opportunities, and any further data you may need to thrive in the aurora kinase b industry. This aurora kinase b market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Aurora kinase B is a protein enzyme that plays a critical role in cell division, particularly during mitosis. It regulates chromosome alignment, segregation, and the proper distribution of genetic material to daughter cells. Aurora kinase B is essential for maintaining genomic stability, and its dysregulation is often linked to various cancers.

The main types of Aurora kinase B inhibitors include AZD-2811, CS-2164, danusertib, ilorasertib, NMI-900, and others. AZD-2811 is a nanoparticle formulation of a potent Aurora kinase B inhibitor, designed for the treatment of solid tumors and hematologic malignancies. It is used for conditions such as anaplastic large cell lymphoma, kidney cancer, lung cancer, prostate cancer, and others. This drug is utilized by various end-users, including hospitals, research institutes, diagnostic laboratories, and other healthcare settings.

The aurora kinase B market consists of sales of aurora kinase B inhibitors, antibodies, diagnostic kits, assay kits, and recombinant proteins. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.